HD-OPM Archive
Hashtags

#cholesterol

111 posts

The longer the lower the better: lifelong LDL lowering and an estimated 60% risk reduction

Nov 20, 2023 · Gokhan Can ♥ 17 · 💬 21 ↩ 2 LDL, ApoB & lipid panel

Argues that the benefit of LDL lowering depends on both how much and how long LDL is reduced. The author, one of the group's admins, is betting on very low-dose statins to hold LDL at 70-100 mg/dL, and estimates about 60% lifetime risk reduction from a 70-point lowering sustained for 30 years. The post also cites Charles Grashow as a case of CAC regression.

Red yeast rice vs statins: lovastatin removed, other monacolins remain, no outcome RCTs

Feb 11, 2024 · Louis Nervegna ♥ 22 · 💬 15 Supplements & vitamins

Louis explains that the FDA forced US red yeast rice products to remove lovastatin (monacolin K), the first statin, approved in 1986 as Mevacor, yet they still lower cholesterol through related monacolins. Some people intolerant of statins tolerate it, but it is unregulated with variable potency and lacks large long-running RCTs proving fewer heart attacks and strokes, so it is a gamble for high-risk people.

2025 ACC statement: inflammation is actionable in CVD, with universal hsCRP screening

Oct 09, 2025 · Gokhan Can ♥ 15 · 💬 13 Inflammation & CRP

Summarises the 2025 ACC Scientific Statement (JACC) concluding the inflammation-ASCVD link is now clinically actionable. It recommends universal hsCRP screening in primary and secondary prevention alongside cholesterol, notes IL-6 and fibrinogen also predict risk, and says CT perivascular fat attenuation is promising but not routine. It contrasts this with a more cautious 2002 CDC/AHA workshop.

Engineered regulatory T cells targeting oxidized LDL cut plaque 70% in mice

Nov 22, 2025 · Gokhan Can ♥ 35 · 💬 7 Inflammation & CRP

Summarises a University of Pennsylvania preclinical study adapting CAR T therapy: Tregs engineered to recognise oxidized LDL dampened arterial inflammation and reduced plaque 70% in cholesterol-prone mice. Unlike cancer CAR-T, the cells suppress rather than destroy; it is a possible add-on for patients at risk despite cholesterol drugs.

Mendelian randomization in 1 million people: statin-like genetics cut dementia risk 76-82%

Nov 06, 2025 · Gokhan Can ♥ 11 · 💬 17 Brain health & dementia

Summarises Dr Stanfield's video on a Mendelian randomization study of over a million people. Short RCTs show no cognitive harm or benefit and observational studies suggest protection; genetic variants mimicking lifelong statin and ezetimibe action were linked to 76-82% relative dementia risk reduction, implying long-term benefit missed by short trials. The video also notes treating hearing loss, vision loss and midlife depression.

Statin RCT meta-analyses show no increase or decrease in cancer risk

Dec 31, 2024 · Louis Nervegna ♥ 11 · 💬 13 Statins

Louis compiles meta-analyses of randomized trials showing statins neither raise nor lower cancer incidence or mortality, plus cohort studies suggesting neutral or lower cancer risk, e.g. prostate cancer. He adds that RCTs and prospective cohorts sit at the top of the evidence hierarchy.

Tissues make their own cholesterol: even very low LDL-C does not impair hormone production

Sep 17, 2026 · Louis Nervegna ♥ 15 · 💬 11 LDL, ApoB & lipid panel

Louis explains that the blood holds only a small fraction of the body's cholesterol and that tissues, including the brain, mostly synthesize what they need. The steroid hormone demand supplied by blood is only tens of milligrams a day, easily met at very low LDL-C. He cites FOURIER and ODYSSEY OUTCOMES, in which LDL-C below 15-20 mg/dL did not impair adrenal or gonadal hormone production or vitamin D.

Microplastics raised plaque 63% in male mice, with no change in cholesterol or weight

Dec 28, 2025 · Gokhan Can ♥ 13 · 💬 12 Environment (microplastics, pollution, heat)

Summarises a UC Riverside mouse study: atherosclerosis-prone mice given 10 mg/kg/day microplastics for nine weeks. Males had 63% more plaque in the aortic root and 624% more in the brachiocephalic artery; females had no significant increase. Weight and cholesterol were unchanged, suggesting direct endothelial damage and inflammation. Admin suggests high fiber and Finnish sauna as defenses (not from the study).

Lipoprotein(a) explained: 80-90% genetic, stable for life, a risk factor beyond LDL

Oct 05, 2024 · Gokhan Can ♥ 12 · 💬 8 Lp(a)

Explainer on Lp(a): an LDL-like particle with apo(a) attached, 80-90% genetically determined, fully expressed by 1-2 years of age, and elevated in about 1 in 5 US individuals (1.4 billion globally). Levels above 50 mg/dL or 125 nmol/L raise ASCVD risk, possibly via impaired fibrinolysis and cholesterol deposition, and may occur with normal lipid panels.

Pooled blinded trials: statins cause only about 1 in 15 reported muscle aches

Oct 23, 2026 · Louis Nervegna ♥ 7 · 💬 12 Statins

A pooled analysis of 19 blinded trials with 123,940 people found that over about four years, 27.1 of 100 on a statin reported muscle pain or weakness versus 26.6 of 100 on placebo. This implies that the vast majority of muscle complaints on statins are not caused by the drug, consistent with a nocebo effect.

Statins work as well in women as men: 27-trial CTT meta-analysis of 174,000 participants

Dec 19, 2023 · Louis Nervegna ♥ 5 · 💬 11 Statins

Louis rebuts the claim that statins are less effective in women using the Cholesterol Treatment Trialists' meta-analysis of 27 randomized trials. Per 1 mmol/L LDL reduction, proportional reductions in major vascular events and all-cause mortality were similar in women and men, with no adverse effect on cancer or non-CV mortality. Trials averaged 4.9 years, so longer-term benefit is likely larger.

Review: aggressive LDL lowering outweighs theoretical risks, yet few reach <55 mg/dL

Oct 28, 2025 · Gokhan Can ♥ 13 · 💬 5 LDL, ApoB & lipid panel

Summarises a July 2025 review: guidelines now target LDL-C <55 mg/dL (<40 after a recurrent event), PCSK9 inhibitors add 59-62% LDL reduction, and evidence (FOURIER, CTT meta-analysis, PCSK9 genetics) supports benefit to very low levels. It says safety concerns such as hemorrhagic stroke, cognitive decline (EBBINGHAUS) and hormone disruption are unsupported, while fewer than one in four high-risk patients reach target.

Psyllium lowers LDL about 13 mg/dL across 28 trials by trapping bile acids

Oct 31, 2026 · Louis Nervegna ♥ 15 · 💬 4 Carbs, fiber, sugar & whole grains

A shared explainer says psyllium lowers LDL by about 13 mg/dL across 28 randomized trials, and that the mechanism is mechanical: its viscous gel traps bile acids so the liver pulls cholesterol from the blood to make more, upregulating LDL receptors. It does not absorb cholesterol directly or scrub the gut, which is why most other soluble fibers do not work the same way.

APOE4 drives cholesterol buildup in brain astrocytes, promoting toxic protein deposits

Oct 06, 2026 · Louis Nervegna ♥ 17 · 💬 4 Brain health & dementia

Mount Sinai researchers using human stem-cell-derived miBrain tissue found APOE4 causes cholesterol to accumulate in astrocytes, impairing lysosomal clearance of alpha-synuclein and promoting amyloid and alpha-synuclein deposits. A second study showed APOE4 damages brain blood vessels through mechanisms unrelated to cholesterol. The poster reads this as cholesterol being potentially causal in APOE4 carriers.

Cholesterol as a master regulator of blood stem cells, driving inflammatory hematopoiesis

Oct 19, 2025 · Gokhan Can ♥ 7 · 💬 4 Inflammation & CRP

Review of preclinical evidence that high LDL pulls hematopoietic stem cells out of dormancy, causing proliferation, oxidative stress, telomere shortening, impaired repopulation and lasting epigenetic changes that program blood and immune cells toward chronic inflammation. This offers a molecular basis for residual inflammatory risk after cholesterol is treated.

Mendelian randomization: BMI, BP, LDL and type 2 diabetes lower odds of longevity

Jan 25, 2025 · Gokhan Can ♥ 5 · 💬 5 LDL, ApoB & lipid panel

A Mendelian randomization study of 46 modifiable risk factors in people of European ancestry found nine linked to longevity (90+ years) and super-longevity (99+). Higher genetically predicted HDL was associated with greater odds of longevity, while higher BMI, obesity, blood pressure, type 2 diabetes, LDL and total cholesterol were associated with lower odds.

LDL is necessary but not always sufficient for atherosclerosis, among 25+ risk factors

Mar 25, 2024 · Louis Nervegna ♥ 14 · 💬 2 LDL, ApoB & lipid panel

Louis summarizes a Joel Kahn video: there are at least 25 major heart disease risk factors, all of which should be addressed, but LDL is special because it appears necessary for plaque to form. It is not always sufficient, since some people with very high LDL never develop plaque. No other risk factor has been shown to be necessary, which is why cardiologists focus on LDL.

Atherosclerosis drivers such as high apoB and blood pressure also raise dementia risk

Jun 05, 2026 · Louis Nervegna ♥ 5 · 💬 5 Brain health & dementia

A shared post argues that atherosclerotic risk factors (atherosclerosis, endothelial dysfunction, high BP, high LDL/apoB) are consistently linked to Alzheimer's and dementia risk, with some genetic overlap between lipids, coronary disease and Alzheimer's. The message is that keeping apoB and blood pressure optimal, and improving endothelial function, insulin sensitivity and inflammation, protects both heart and brain.

Higher LDL linked to undereye bags and full cheeks in faster facial aging

Sep 28, 2024 · Louis Nervegna ♥ 6 · 💬 4 Aging & longevity

Louis shares a National Geographic piece on 3D facial imaging used to estimate biological age. Higher LDL and total cholesterol tracked with undereye bags and full cheeks, while inflammation and infection tracked with a narrowing forehead and sagging skin. Smoking, snoring and high cholesterol marked fast-agers, whereas yogurt, regular mealtimes and denser bones marked slow-agers.

Statins cause under 10% of reported muscle pain, analysis of 23 RCTs finds

Jun 29, 2026 · Louis Nervegna ♥ 6 · 💬 2 Statins

Louis shares the Oxford/CTT Lancet analysis of 23 large randomized trials (155,000 people) showing muscle pain is common with or without a statin. Over 90% of muscle pain reported on statins was not caused by the drug, and true statin-related cases occurred mainly in the first year, more with high-intensity dosing.

Serious statin muscle side effects (myopathy) are rare; benign aches are common

Jun 29, 2026 · Louis Nervegna ♥ 6 · 💬 5 Statins

Louis notes that a large new study confirms benign muscle aches are fairly common but serious statin-related muscle problems are rare. The shared Duke post says concern about side effects exceeds the evidence and points to the PREVENTABLE trial of statins in older adults without cardiovascular disease.

Fibrates lower triglycerides and may reduce CVD risk in metabolic syndrome

Mar 01, 2024 · Gokhan Can ♥ 5 · 💬 3 LDL, ApoB & lipid panel

Brief overview of fibrates (fenofibrate, gemfibrozil), PPAR-alpha agonists that lower triglycerides, raise HDL and have anti-inflammatory effects. Meta-analyses and real-world data suggest a role for CVD risk reduction in people with metabolic syndrome, especially high triglycerides and low HDL. A 2020 review notes that several RCTs did not show clear benefit overall.

Swapping refined carbs for unsaturated fat lowers LDL: meta-analysis of 60 feeding trials

Oct 08, 2025 · Louis Nervegna ♥ 5 · 💬 2 Fats & oils (saturated fat, seed oils, omega-6, olive oil)

A meta-analysis of 60 controlled human feeding trials found that replacing carbohydrate calories with monounsaturated or polyunsaturated fat lowers LDL cholesterol, while saturated fat raises it. The effect looked largest for polyunsaturated fat, which is why choosing oils and nuts over refined starch and sugar helps the lipid profile.

Nearly every cell makes its own cholesterol, especially brain cells

Oct 29, 2026 · Louis Nervegna ♥ 4 · 💬 2 LDL, ApoB & lipid panel

Louis notes that nearly every nucleated cell synthesizes its own cholesterol rather than relying on blood cholesterol, particularly cells in the brain. The shared explainer describes cholesterol biosynthesis through the mevalonate pathway with HMG-CoA reductase as the rate-limiting step. It frames why circulating cholesterol and tissue cholesterol are largely separate pools.

North Karelia: swapping butter for vegetable oils credited with 80%+ fewer coronary deaths

Louis says replacing saturated with unsaturated fat is believed to be a main reason heart deaths dropped in Finland in the 1970s and 1980s. The shared cardiologist's post describes North Karelia's 700 per 100,000 CVD death rate in 1972, with 24% of calories from saturated fat, and a 20% cholesterol drop with coronary deaths in working-age men falling 82%.

Fiber and longevity: observational links plus RCTs showing better risk factors

Oct 06, 2026 · Louis Nervegna ♥ 2 · 💬 1 Carbs, fiber, sugar & whole grains

A summary explaining that most evidence linking fiber to longer life is observational but consistent across countries and populations. Randomized trials, though too short for mortality, show fiber improves glucose, HbA1c, insulin resistance, blood pressure and LDL. The lack of a decades-long mortality trial is not evidence of no benefit.

New Scientist: most statin label side effects are not caused by statins

Feb 11, 2026 · Louis Nervegna ♥ 1 · 💬 2 Statins

Shared news report on a rigorous assessment of the evidence concluding that the long list of statin side effects is vastly overstated and that package warnings may be deterring people from life-saving drugs. The investigator quoted says we can now be confident statins do not cause the vast majority of listed issues.

Possible, mostly unproven natural ways to lower Lp(a) after statins leave it high

Jan 28, 2025 · Louis Nervegna ♥ 4 Lp(a)

Louis shares a question from a member who started statins and saw large improvements in cholesterol and triglycerides but still has high Lp(a). He points to the comments for possible natural approaches, stressing that little if any of this is proven. Since no other effective treatment for high Lp(a) was available, some might be worth trying, with caution.

Berberine 500 mg twice daily lowered ApoB in two trials; CVD prevention unproven

Oct 29, 2026 · Louis Nervegna ♥ 1 Supplements & vitamins

A shared summary says two randomized trials of 500 mg berberine twice daily reduced ApoB, with a reduction nearly three times greater in women, though across separate trials. A newer study of 84 men identified a 'Berberine Signature' of 92 proteins linked to about 13% lower odds of ischemic heart disease in UK Biobank, but those participants were not necessarily taking berberine, so it does not prove prevention.

200+ studies and 2 million participants show LDL drives atherosclerosis dose-dependently

Oct 28, 2026 · Louis Nervegna ♥ 1 LDL, ApoB & lipid panel

A shared post rebuts a claim that LDL research is incomplete and flawed. It cites over 200 prospective cohort, genetic and randomized studies involving over 2 million participants, 20 million person-years and 150,000+ cardiovascular events that consistently show a dose-dependent LDL-ASCVD relationship. It also addresses the U-shaped curve claim and Mendelian randomization.